Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Twist Bioscience CorpTWST · Entity 3619 | President and COO | October 02, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Twist Bioscience Corp
Report date October 02, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,088 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 25,714 · Balance 185,088 F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2021 Filed Apr 5, 2021 22:32 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 256 | $122.20 | $31,283.20 |
DisclosureSEC source: 0001214659-21-003955 · ownership.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,744 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| April 01, 2021 Filed Apr 7, 2021 14:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 256 | $122.20 | $31,283.20 |
DisclosureSEC source: 0001214659-21-003997 · marketforms-52190.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,744 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:46 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 827 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-002724 · marketforms-51700.xml · derivative · entry 7 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,475 Underlying: Common Stock · 827 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:46 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-002724 · marketforms-51700.xml · derivative · entry 6 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,544 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:46 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-002724 · marketforms-51700.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,773 Underlying: Common Stock · 358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:46 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,702 | $145.35 | $392,735.70 |
DisclosureSEC source: 0001214659-21-002724 · marketforms-51700.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:46 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 827 | $23.33 | $19,293.91 |
DisclosureSEC source: 0001214659-21-002724 · marketforms-51700.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:46 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-21-002724 · marketforms-51700.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:46 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 358 | $8.82 | $3,157.56 |
DisclosureSEC source: 0001214659-21-002724 · marketforms-51700.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:48 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 183 | $134.31 | $24,578.73 |
DisclosureSEC source: 0001214659-21-002456 · marketforms-51651.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:56 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $150.81 | $154,881.87 |
DisclosureSEC source: 0001214659-21-002302 · marketforms-51556.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,183 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 827 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-001271 · marketforms-51368.xml · derivative · entry 7 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,302 Underlying: Common Stock · 827 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-001271 · marketforms-51368.xml · derivative · entry 6 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,061 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-001271 · marketforms-51368.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,131 Underlying: Common Stock · 358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,702 | $183.59 | $496,060.18 |
DisclosureSEC source: 0001214659-21-001271 · marketforms-51368.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,027 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 827 | $23.33 | $19,293.91 |
DisclosureSEC source: 0001214659-21-001271 · marketforms-51368.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-21-001271 · marketforms-51368.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 358 | $8.82 | $3,157.56 |
DisclosureSEC source: 0001214659-21-001271 · marketforms-51368.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 22:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 201 | $190.64 | $38,318.64 |
DisclosureSEC source: 0001214659-21-000831 · marketforms-51254.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,027 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 827 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-000267 · marketforms-50890.xml · derivative · entry 7 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,129 Underlying: Common Stock · 827 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-000267 · marketforms-50890.xml · derivative · entry 6 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,578 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-000267 · marketforms-50890.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,489 Underlying: Common Stock · 358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,702 | $132.93 | $359,176.86 |
DisclosureSEC source: 0001214659-21-000267 · marketforms-50890.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,228 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 827 | $23.33 | $19,293.91 |
DisclosureSEC source: 0001214659-21-000267 · marketforms-50890.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-21-000267 · marketforms-50890.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 358 | $8.82 | $3,157.56 |
DisclosureSEC source: 0001214659-21-000267 · marketforms-50890.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:55 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 194 | $141.29 | $27,410.26 |
DisclosureSEC source: 0001214659-21-000153 · marketforms-50802.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,228 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,754 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-20-010284 · marketforms-50578.xml · derivative · entry 11 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,956 Underlying: Common Stock · 10,754 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,089 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-20-010284 · marketforms-50578.xml · derivative · entry 10 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,095 Underlying: Common Stock · 9,089 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 20% of the shares subject to the option vested on October 31, 2019, and 1/60th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,002 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-20-010284 · marketforms-50578.xml · derivative · entry 9 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,847 Underlying: Common Stock · 6,002 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 200 | $134.27 | $26,853.00 |
DisclosureSEC source: 0001214659-20-010284 · marketforms-50578.xml · nonDerivative · entry 8 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,422 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $134.22 to $134.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 661 | $133.16 | $88,017.97 |
DisclosureSEC source: 0001214659-20-010284 · marketforms-50578.xml · nonDerivative · entry 7 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,622 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $132.99 to $133.36 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,026 | $132.32 | $665,062.43 |
DisclosureSEC source: 0001214659-20-010284 · marketforms-50578.xml · nonDerivative · entry 6 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,283 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $131.97 to $132.95 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 13,911 | $131.38 | $1,827,632.74 |
DisclosureSEC source: 0001214659-20-010284 · marketforms-50578.xml · nonDerivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,309 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $130.95 to $131.94 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,047 | $130.65 | $790,015.76 |
DisclosureSEC source: 0001214659-20-010284 · marketforms-50578.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,220 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $129.94 to $130.92 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 10,754 | $23.33 | $250,890.82 |
DisclosureSEC source: 0001214659-20-010284 · marketforms-50578.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 9,089 | $26.66 | $242,312.74 |
DisclosureSEC source: 0001214659-20-010284 · marketforms-50578.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 6,002 | $8.82 | $52,937.64 |
DisclosureSEC source: 0001214659-20-010284 · marketforms-50578.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 22:55 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 967 | $115.56 | $111,746.52 |
DisclosureSEC source: 0001214659-20-009875 · marketforms-50157.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,422 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| October 24, 2020 Filed Oct 27, 2020 20:49 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,149 | $85.97 | $98,779.53 |
DisclosureSEC source: 0001214659-20-008875 · marketforms-49870.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,389 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 00:36 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 7,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-007681 · marketforms-49587.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,538 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of October 1, 2020, for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 01, 2020 Filed May 23, 2023 20:10 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantEmployee Stock Option (right to buy) · Derivative | 23,355 | $0.00 Strike: $67.85 | $0.00 |
DisclosureSEC source: 0001214659-23-007733 · marketforms-61594.xml · derivative · entry 2 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,355 Underlying: Common Stock · 23,355 shares Expires 2030-08-31 F2 · balance_after: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 20:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-20-007647 · marketforms-49551.xml · derivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,849 Underlying: Common Stock · 2,358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 29, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 20:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 2,358 | $8.82 | $20,797.56 |
DisclosureSEC source: 0001214659-20-007647 · marketforms-49551.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 23:11 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,708 | $67.47 | $115,238.93 |
DisclosureSEC source: 0001214659-20-007560 · marketforms-49536.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,390 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 22, 2019. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $67.01 to $67.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 23:11 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 650 | $66.55 | $43,256.53 |
DisclosureSEC source: 0001214659-20-007560 · marketforms-49536.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,098 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 22, 2019. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $65.98 to $66.89 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:40 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 967 | $67.28 | $65,059.76 |
DisclosureSEC source: 0001214659-20-007445 · marketforms-49488.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,748 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:46 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-20-006767 · marketforms-49377.xml · derivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,207 Underlying: Common Stock · 2,358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 29, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:46 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 2,358 | $8.82 | $20,797.56 |
DisclosureSEC source: 0001214659-20-006767 · marketforms-49377.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:42 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-20-006766 · marketforms-49377.xml · derivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,207 Underlying: Common Stock · 2,358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 29, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.